Peplomycin and bleomycin effects on human colon cancer cells. 1986

A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff

The lethal effects of peplomycin and bleomycin on cultured human colon cancer cells (LoVo) were compared by using the technique of inhibition of colony formation. The survival of LoVo cells after treatment for 1 h with either peplomycin or bleomycin was characterized by a biphasic exponential curve. When the exposure time was extended to 24 h, both drugs produced much greater cytotoxic effects, with survival decreased to less than 0.10% for bleomycin and less than 0.02% for peplomycin. Both peplomycin and bleomycin, in a dose-dependent manner, inhibited the incorporation of thymidine into cells. On an equal-weight basis, the cytotoxicity of peplomycin (24-h exposure) was similar to that of bleomycin. Both agent also inhibited the incorporation of leucine and uridine after 24 h of drug exposure, but to a lesser extent than inhibition of thymidine incorporation. However, after 1 h of exposure, such inhibitory effects were minimal. These results demonstrate that prolonged peplomycin or bleomycin exposure produces greater cell-kill than shorter drug exposure. Schedules with continuous drug administration should be explored clinically.

UI MeSH Term Description Entries
D007930 Leucine An essential branched-chain amino acid important for hemoglobin formation. L-Leucine,Leucine, L-Isomer,L-Isomer Leucine,Leucine, L Isomer
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D003114 Colony-Forming Units Assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity. Clonogenic Cell Assay,Stem Cell Assay,Clonogenic Cell Assays,Colony Forming Units Assays,Colony-Forming Units Assays,Stem Cell Assays,Assay, Clonogenic Cell,Assay, Colony-Forming Units,Assay, Stem Cell,Assays, Clonogenic Cell,Assays, Colony-Forming Units,Assays, Stem Cell,Colony Forming Units Assay
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D014529 Uridine A ribonucleoside in which RIBOSE is linked to URACIL. Allo-Uridine,Allouridine,Allo Uridine
D017663 Peplomycin An antineoplastic agent derived from BLEOMYCIN. Pepleomycin,NK-631,Peplomycin Sulfate,Peplomycin Sulfate (1:1),NK 631,NK631,Sulfate, Peplomycin

Related Publications

A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
January 1986, Journal of cancer research and clinical oncology,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
October 1981, Nihon Gan Chiryo Gakkai shi,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
April 1984, Cancer research,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
June 2001, Oral oncology,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
January 1987, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
October 2009, International immunopharmacology,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
March 1984, The Journal of antibiotics,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
April 2005, World journal of gastroenterology,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
January 2003, Oncology reports,
A Uematsu, and D H Ho, and B Drewinko, and L Y Yang, and N S Brown, and G P Bodey, and I H Krakoff
October 2010, Journal of agricultural and food chemistry,
Copied contents to your clipboard!